NO PATCH GEL

Large database analysis examining niacinamide's potential role in skin cancer prevention through supplementation.

Not specified in abstract provided Journal of the American Academy of Dermatology. 2026. PubMed →

Research indicates that neutral pH (7.4) formulations increase niacinamide skin permeation approximately twofold compared to acidic pH (5.0), with corresponding changes in stratum corneum electrical properties facilitating enhanced transdermal delivery. Studies employed Franz cell diffusion experiments and electrical impedance spectroscopy using human skin models to characterize pH-dependent permeation mechanisms.

Not specified in abstract provided Scientific Reports. 2026. PubMed →

Research indicates that dissolving microneedle patches containing niacinamide exhibit greater skin-lightening effects than traditional topical formulations for treating melasma and post-inflammatory hyperpigmentation. Clinical studies have validated safety and efficacy with minimal adverse effects when using advanced transdermal delivery systems.

Not specified in abstract provided Recent Advances in Drug Delivery and Formulation. 2026. PubMed →

Systematic umbrella review evaluating nutritional supplements including niacinamide for primary prevention of skin diseases across 9,229 participants, examining preventive effects against ultraviolet radiation-induced skin pathology and other dermatological conditions.

Not specified in abstract provided Preventive Nutrition and Food Science. 2026. PubMed →

Research comparing glabridin with niacinamide as recognized inhibitor of melanosome transfer in UVB-irradiated co-culture systems demonstrated complementary mechanisms for reducing melanin transfer from melanocytes to keratinocytes through dendrite suppression pathways.

Not specified in abstract provided Pharmaceuticals (Basel, Switzerland). 2026. PubMed →

Real-world case series of 5% tranexamic acid serum demonstrated that application after in-office pigment-targeting procedures (non-ablative laser, microneedling, salicylic acid peel) may accelerate improvement in dyspigmentation. Studies suggest the combination approach offered added benefits of improved skin texture and radiance when integrated into comprehensive skincare regimens.

Journal of Drugs in Dermatology Journal of Drugs in Dermatology. 2026. PubMed →

Randomized controlled trial compared microneedling and intradermal injection approaches for tranexamic acid delivery in melasma treatment. Research indicates both delivery methods demonstrated efficacy, though the study highlights melasma's challenge of resistance to treatment and high relapse tendency.

Indian Journal of Dermatology Indian Journal of Dermatology. 2026. PubMed →

Research indicates that melasma in Fitzpatrick skin types III-V demonstrates high relapse rates and chronic persistence. Studies suggest addressing cytokine-driven inflammation and visible light-induced melanogenesis supports rationale for multimodal therapeutic approaches combining topical agents with procedural interventions.

Journal of Cosmetic Dermatology Journal of Cosmetic Dermatology. 2026. PubMed →

Evidence indicates that Fitzpatrick skin types III-VI experience increased risk of post-inflammatory hyperpigmentation with more pronounced dyspigmentation. Research suggests pathophysiology involves complex pathways including UV radiation, local inflammation, and cytokine signaling, highlighting need for prompt management to prevent months-to-years persistence.

Journal of Cutaneous Medicine and Surgery Journal of Cutaneous Medicine and Surgery. 2026. PubMed →

Research indicates that microneedle patches containing tranexamic acid exhibit greater skin-lightening effects than traditional topical formulations. Clinical studies have validated safety and efficacy in reducing melasma and post-inflammatory hyperpigmentation with minimal adverse effects through enhanced transdermal delivery.

Recent Advances in Drug Delivery and Formulation Recent Advances in Drug Delivery and Formulation. 2026. PubMed →